OMERS ADMINISTRATION Corp Buys Shares of 100,943 Biodesix, Inc. (NASDAQ:BDSX)

OMERS ADMINISTRATION Corp bought a new stake in shares of Biodesix, Inc. (NASDAQ:BDSX) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 100,943 shares of the company’s stock, valued at approximately $154,000. OMERS ADMINISTRATION Corp owned 0.07% of Biodesix at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of BDSX. Samjo Management LLC acquired a new position in Biodesix during the 4th quarter valued at about $3,790,000. Susquehanna International Group LLP increased its stake in Biodesix by 769.8% during the 4th quarter. Susquehanna International Group LLP now owns 1,115,748 shares of the company’s stock valued at $1,707,000 after buying an additional 987,475 shares during the period. Silverarc Capital Management LLC increased its stake in Biodesix by 21.7% during the 4th quarter. Silverarc Capital Management LLC now owns 4,332,281 shares of the company’s stock valued at $6,628,000 after buying an additional 771,187 shares during the period. AIGH Capital Management LLC increased its stake in Biodesix by 8.8% during the 4th quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company’s stock valued at $9,455,000 after buying an additional 500,000 shares during the period. Finally, Perkins Capital Management Inc. increased its stake in Biodesix by 46.3% during the 4th quarter. Perkins Capital Management Inc. now owns 1,060,211 shares of the company’s stock valued at $1,622,000 after buying an additional 335,429 shares during the period. Institutional investors and hedge funds own 20.96% of the company’s stock.

Analysts Set New Price Targets

BDSX has been the topic of several research analyst reports. Craig Hallum lowered their target price on shares of Biodesix from $3.00 to $1.50 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. Lake Street Capital lowered their price objective on shares of Biodesix from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. William Blair reaffirmed a “market perform” rating on shares of Biodesix in a research note on Wednesday, May 14th. Finally, Canaccord Genuity Group lowered their price objective on shares of Biodesix from $2.50 to $1.50 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $2.00.

Biodesix Stock Performance

Shares of BDSX opened at $0.27 on Wednesday. Biodesix, Inc. has a one year low of $0.17 and a one year high of $2.04. The company has a 50-day moving average of $0.55 and a two-hundred day moving average of $0.96. The stock has a market cap of $39.69 million, a price-to-earnings ratio of -0.69 and a beta of 1.18. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40.

Biodesix (NASDAQ:BDSX) last announced its earnings results on Tuesday, May 13th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. The company had revenue of $17.96 million during the quarter, compared to analysts’ expectations of $19.50 million. On average, equities research analysts expect that Biodesix, Inc. will post -0.35 earnings per share for the current year.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.